We generally advise against it if you have any of the following: History of Medullary Thyroid Cancer: The drug is a GLP-1 receptor agonist, which has been shown to cause recurrences of thyroid tumors in patients with a history of it
That's starting smart
tirzepatide activates two (GLP-1 + GIP), which is why the entire Semaglutide vs Tirzepatide comparison flows from single- versus dual-pathway signalling
PlexusDx recommends rotating to a new location each week across your abdomen, thighs, and upper arms to maintain healthy skin and consistent results
Retatrutide works as a powerful triple-agonist, meaning it works on three key hormone receptors: The human glucagon receptor (GCGR) The glucose-dependent polypeptide receptor (GIP receptor) The glucagon-like peptide-1 receptor (GLP-1) This unique receptor profile allows retatrutide to effectively: Regulate appetite, feelings of fullness, and gastric emptying Regulate metabolism Regulate blood sugar levels The activation of the GIP, GLP-1, and GCG receptors simultaneously by retatrutide leads to better weight reduction and cardiometabolic benefits compared to targeting a single receptor
1 The MHRA approved it for cardiovascular risk reduction in July 2024, making it the first weight-loss medication with this indication in the UK
